The Research Letter titled “Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials,”1 published online first on March 4, 2019, and in the April 2019 print issue of JAMA Internal Medicine, contained an analysis that should not have been counted, and further analysis uncovered 2 coding errors. When these errors were corrected, the main conclusions of the original publication did not change, but the point estimates and percentages of the results were increased. A full explanation of these errors is provided in an accompanying Letter to the Editor,2 and the article has been corrected online.
1.Garmendia
CA, Nassar Gorra
L, Rodriguez
AL, Trepka
MJ, Veledar
E, Madhivanan
P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses: the example of the apixaban trials.
JAMA Intern Med. 2019;179(4):582-584. doi:
10.1001/jamainternmed.2018.7661PubMedGoogle ScholarCrossref